| Code | CSB-MP4304MOV |
| Abbreviation | Recombinant Cynomolgus monkey CLDN18.2 protein-VLPs (Active) |
| MSDS | |
| Size | $620 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
Claudin 18.2 has emerged as a high-priority therapeutic target in oncology due to its restricted expression pattern and surface accessibility on tumor cells, yet its four-transmembrane topology makes soluble recombinant production notoriously difficult. This Macaca fascicularis CLDN18.2 construct (full-length, aa 1–261) overcomes that challenge by presenting the protein in virus-like particles (VLPs) derived from mammalian cells, preserving native conformation and extracellular loop architecture critical for antibody epitope recognition. Functional ELISA confirms robust binding to an anti-CLDN18.2 recombinant antibody (CSB-RA005498A1HU) with an EC50 of 2.806–3.641 ng/ml, directly supporting antibody development, cross-reactivity screening against cynomolgus orthologs, and validation of therapeutic candidates targeting CLDN18.2 in tumor metastasis research. The VLP format, combined with endotoxin levels below 1.0 EU/μg, provides a suitable basis for immunization protocols and cell-based binding assays where conformational integrity is essential.
There are currently no reviews for this product.